Company: MIRM
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001759425-25-000003
Chunk: 0

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition.

On January 13, 2025, Mirum Pharmaceuticals, Inc. (the “ Company”) issued a press release announcing, among other things, the Company's preliminary unaudited net product sales for the fiscal year ended December 31, 2024, preliminary unaudited net product sales of LIVMARLI (maralixibat) oral solution and CHOLBAM and CHENODAL, and preliminary unaudited cash, cash equivalents and investments. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.